Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.

Illumina Inc (ILMN) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart


See More
  • Market Capitalization, $K 19,558,270
  • Shares Outstanding, K 146,600
  • Annual Sales, $ 2,220 M
  • Annual Income, $ 462 M
  • 36-Month Beta 1.18
  • Price/Sales 8.45
  • Price/Book 8.07

Price Performance

See More
Period Period Low Period High Performance
126.39 +1.19%
on 12/01/16
145.43 -12.05%
on 11/09/16
-7.76 (-5.72%)
since 11/02/16
126.39 +1.19%
on 12/01/16
186.88 -31.56%
on 10/06/16
-40.00 (-23.82%)
since 09/02/16
126.39 +1.19%
on 12/01/16
196.47 -34.90%
on 12/30/15
-53.70 (-29.57%)
since 12/02/15

Most Recent Stories

More News
MedTech Sails Through Macro Woes: Stocks in Focus

MedTech Sails Through Macro Woes: Stocks in Focus

Mass Spectrometry Adopted by Clinical Laboratories Around the World

Mass spectrometry (MS) is a highly selective analytic technique which provides significantly more accurate measurements and as a result, is now being used in an increasing number of clinical laboratories....

Illumina and Mayo Clinic Form Bioinformatics Relationship to Advance Genetic Disorder Testing

Illumina, Inc. (NASDAQ: ILMN) today announced it has entered an agreement with Mayo Clinic to make advancements in next-generation sequencing technology with the intent to accelerate...

WAVE Life Sciences Appoints Christian Henry to its Board of Directors

WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced the appointment of Christian...

Illumina Launches TruSight Tumor 170 for Tumor Profiling

Illumina, Inc. (ILMN), a major provider of medical devices, recently launched TruSight Tumor 170 ??? a 170 gene next-generation sequencing solution for research use only.

Everyone Wins as the Election Ends

Everyone Wins as the Election Ends

Research Reports Coverage on Biotech Stocks -- Illumina, Peregrine Pharma, Lexicon Pharma, and Vanda Pharma

In today's pre-market research, presents four Biotech equities for review: Illumina Inc. (NASDAQ: ILMN), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Lexicon Pharmaceuticals Inc. (NASDAQ:...

Illumina Launches TruSight Tumor 170

Illumina, Inc. (NASDAQ:ILMN) today announced the launch of TruSight(R) Tumor 170, a 170 gene next-generation sequencing solution to support the transformation of the tumor-profiling...

New Strong Sell Stocks for November 3rd

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday

Downgrade Alert for Illumina (ILMN)

Illumina (NASDAQ:ILMN) was downgraded from Equal-Weight to Underweight at First Analysis today. The stock closed yesterday at $135.66 on volume of 2.5 million shares, above average daily volume of 1.8...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Illumina Inc. is a leading developer of next-generation tools for the large-scale analysis of genetic variation and function. The company's tools will provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. The company is developing...

See More

Support & Resistance

2nd Resistance Point 129.44
1st Resistance Point 128.67
Last Price 127.90
1st Support Level 127.02
2nd Support Level 126.14

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.